I. Steadfast Original Aspiration: Anchoring Development Direction with Our Mission
“Achieving technological self-reliance and strength, overcoming ‘chokehold’ challenges, and ensuring the security of the pharmaceutical industry chain; inheriting and innovating traditional Chinese medicine to safeguard human health.” This is the core mission etched into the very DNA of [Company Name]’s development.
Since its establishment, the company has consistently focused on the core track of pharmaceutical manufacturing, directly addressing the industry’s pain points: long-term reliance on imported high-end pharmaceutical excipients, slow progress in the modernization of traditional Chinese medicine, and insufficient competitiveness in the international market… Based on this, the company has clearly defined its development positioning—becoming a leading domestic provider of high-end pharmaceutical lipid excipients, specialty anti-cancer APIs, and Ganoderma health products; becoming a leader in the modernization of traditional Chinese medicine through technological innovation; breaking down industry barriers with technological innovation; safeguarding public health with unwavering quality; and integrating into the global industrial chain through an open strategy.
From initially producing a single product to now covering APIs, health products, and technical services—a diversified business system; from deep cultivation of the domestic market to product deployment in more than 20 countries and regions worldwide, [Company Name] has always been guided by its mission, steadily advancing on the track of the pharmaceutical industry. To date, it has served over 1,000 customers, established deep partnerships with leading domestic and international companies such as AstraZeneca and Qilu Pharmaceutical, and demonstrated the responsibility and commitment of a pharmaceutical enterprise through its strength.
II. Craftsmanship Builds Products: Solidifying the Brand Foundation with Quality
“Medicine concerns people’s lives.” Quality is the lifeline of a pharmaceutical enterprise and also the core principle that [Company Name] steadfastly upholds.
At the raw material stage, the company rigorously selects authentic medicinal materials and high-quality raw materials, controlling quality from the source to ensure that every batch of raw materials meets stringent standards. At the production stage, relying on its core production base in Conghua, Guangzhou, the company strictly adheres to GMP regulations, achieving standardized and meticulous control over the production process. The production center employs 131 professional staff who work diligently on the front lines, meticulously refining every step of the process. At the quality stage, the quality center’s 42 professionals have established a full-process testing system, conducting rigorous tests on over 100 indicators such as product purity, stability, and safety, ensuring that every product passes international authoritative certifications such as EU CEP and US FDA US-DMF, reaching internationally leading levels.
In the field of high-end pharmaceutical excipients, the company has broken the monopoly of international products, providing domestic alternatives for the pharmaceutical industry, reducing production costs for enterprises while ensuring the safety of drug production. In the field of health supplements and health products, the company leverages technology to empower traditional wellness wisdom, creating high-quality categories such as Ganoderma health products, providing scientific and effective health solutions for mid-to-high-end consumers. In the field of technical services, the company delves deeply into the modernization of traditional Chinese medicine, providing integrated and implementable technical solutions to the industry, thereby promoting the standardization and modernization of traditional Chinese medicine.
III. Innovation Breaks the Impasse: Driving Industrial Upgrading with Technology
Innovation is the core driving force behind [Company Name]’s breakthrough of development bottlenecks and leading the industry forward.
The company relies on two major R&D centers in Haizhu, Guangzhou, and Hengqin, Zhuhai, bringing together 48 core R&D personnel, focusing on two key areas: R&D of high-end pharmaceutical excipients and upgrading technologies for the modernization of traditional Chinese medicine. It continuously increases R&D investment, breaking through multiple technical challenges in the industry. Addressing the issue of import dependence on high-end pharmaceutical excipients, the company conducts technological research and achieves mass production of several core excipients domestically, providing support for the autonomous and controllable pharmaceutical industry chain. Regarding the industry pain point of “pills, powders, pastes, and elixirs—hard to distinguish even for immortals” in traditional Chinese medicine, the company uses modern technology to interpret traditional Chinese medicine formulas, promoting the transformation of traditional Chinese medicine production from “experience-based decoction” to “scientific pharmaceutical manufacturing,” thus providing replicable technical solutions for the modernization of traditional Chinese medicine.
At the same time, the company has built a “production-direct sales + agency distribution + custom processing + technical service composite model,” not only providing customers with high-quality products but also offering customized technical support and services—from formula optimization and process improvement to product testing—providing all-round assistance to customers in enhancing their product competitiveness and becoming a core partner for many pharmaceutical companies.
IV. Global Layout: Integrating into the World Through Openness
In the wave of globalization, [Company Name] adheres to the open development philosophy of “based in China, going global,” actively integrating into the global pharmaceutical industry chain.
The company’s products are exported to more than 20 countries and regions worldwide, with international certification systems covering major pharmaceutical markets such as the EU, the United States, Mexico, and India, earning widespread recognition from the international industry. In terms of international market expansion, the company actively participates in international exhibitions such as Russia’s IPhEB, China’s API, and the Saudi-China Entrepreneurs Forum, showcasing the technological strength and brand image of Chinese pharmaceutical enterprises to the world, and promoting the entry of Chinese pharmaceutical technology and products onto the international stage.
In the domestic market, the company has built a marketing network covering all 31 provinces, municipalities, and autonomous regions across the country, establishing sales offices and agents to achieve nationwide reach for its products and services. At the same time, it is planning to build a 15,000-square-meter Guangzhou Conghua Pharmaceutical and Health Industry Complex, creating an industrial platform that integrates R&D, testing, exhibition, and e-commerce, promoting industrial agglomeration and resource integration, further consolidating the foundation of the domestic market.
V. Looking Far Ahead: Building a Healthy Future Through Shared Responsibility
Standing at a new starting point for development, [Company Name] will continue to uphold its original aspiration, taking innovation as its wings, quality as its foundation, and openness as its path, continuously deepening R&D and global deployment, accelerating the localization of high-end pharmaceutical excipients, and supporting the high-quality development of the modernization of traditional Chinese medicine.
In the future, the company will continue to collaborate with domestic and international partners to jointly build an open and win-win industrial ecosystem, providing higher-quality domestic alternative products and technical services to the pharmaceutical industry, offering more scientific health solutions to consumers, contributing Chinese strength to the development of the global pharmaceutical industry, and putting into practice the original aspiration and mission of “safeguarding human health” through concrete actions, thus writing a new chapter in the building of a powerful pharmaceutical nation.
